RT @veitchemma: read these 2 now back to back and main thought is, why consort 4 noninferiority didn't anticipate potential 4 directional b…
L’article de Vinay Prasad sur la non-infériorité est excellentissime. Merci @docdu16 ! (Finalement 2 lapins) https://t.co/GJlb9A3wrW
@doc_ccc Hospitalizations & return to Clinic greater in NT group. 🤔 Good read on NI trials. https://t.co/gmgwiE9AHt
RT @veitchemma: read these 2 now back to back and main thought is, why consort 4 noninferiority didn't anticipate potential 4 directional b…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @jturnesv: Sobre la utilización perversa de los diseños de no inferioridad en #ensayosclinicos y su correcta interpretación en este magn…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @billmeikrantz: “Is the new therapy cheaper, more convenient, less invasive, or less toxic than the older one? If the answer is no, read…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
RT @nedalai: Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinici…
Great review from @VinayPrasad82 in why non-inferiority trials may actually be inferior, so to speak. A must read for clinicians. https://t.co/KwGD4LLc6L @JournalGIM
RT @MDaware: roses in vases medications in vials @VinayPrasad82 has some issues with non-inferiority trials: https://t.co/LBQ9gYEjI6 https…
RT @jonathan_giftos: Great overview of the problems associated with non-inferiority trial design and interpretation by Dr. Vinay Prasad in…
RT @jonathan_giftos: Great overview of the problems associated with non-inferiority trial design and interpretation by Dr. Vinay Prasad in…
RT @jonathan_giftos: Great overview of the problems associated with non-inferiority trial design and interpretation by Dr. Vinay Prasad in…
RT @jonathan_giftos: Great overview of the problems associated with non-inferiority trial design and interpretation by Dr. Vinay Prasad in…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @MDaware: roses in vases medications in vials @VinayPrasad82 has some issues with non-inferiority trials: https://t.co/LBQ9gYEjI6 https…
Music & medicine? Now, medicine & poetry! https://t.co/CfXo3aDnND
roses in vases medications in vials @VinayPrasad82 has some issues with non-inferiority trials: https://t.co/LBQ9gYEjI6 https://t.co/5YrkM31LWU
RT @PabloRichly: Los estudios de no inferioridad parecen ser un diseño hecho para no fracasar. Tenerlo en cuenta a la hora de evaluar "evid…
Sobre la utilización perversa de los diseños de no inferioridad en #ensayosclinicos y su correcta interpretación en este magnífico y sorprendentemente ameno editorial 👉https://t.co/2hQgMEileD de @VinayPrasad82 lleno de prácticos consejos @JuanAbraldes @elm
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @ProfDFrancis: Shrewd article from Vinay Prasad on what to consider when reading a non-inferiority trial. If interest, I can cover this…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @PabloRichly: Los estudios de no inferioridad parecen ser un diseño hecho para no fracasar. Tenerlo en cuenta a la hora de evaluar "evid…
RT @PabloRichly: Los estudios de no inferioridad parecen ser un diseño hecho para no fracasar. Tenerlo en cuenta a la hora de evaluar "evid…
Los estudios de no inferioridad parecen ser un diseño hecho para no fracasar. Tenerlo en cuenta a la hora de evaluar "evidencia". https://t.co/o6s9JEC1jr
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @RogueRad: Clear explanation of non inferior trials by @VinayPrasad82., which seem like RCT's version of participation trophies https://…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
Non Inferiority trial = supermarket of Direct Oral Anticoagulant https://t.co/9Q0dd2PTQI
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @barttels2: My least favorite term just got a little more least-favorited. Beautifully composed & argued. Yes, buyer ~~ and for mercy's…
RT @RogueRad: Clear explanation of non inferior trials by @VinayPrasad82., which seem like RCT's version of participation trophies https://…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @ProfDFrancis: Shrewd article from Vinay Prasad on what to consider when reading a non-inferiority trial. If interest, I can cover this…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
RT @SoberaniaSalud: ¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el t…
¿El paciente como prioridad? Un estudio de no inferioridad muestra si una nueva droga es al menos tan eficaz como el tratamiento en uso. Pero para que sea beneficiosa debe ser menos invasiva, menos tóxica y más barata para el paciente. 📄 https://t.co/LpP
RT @veitchemma: When my brain is functioning again (might be a long time), I will read this https://t.co/aIfWa4OT9O
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @ProfDFrancis: Shrewd article from Vinay Prasad on what to consider when reading a non-inferiority trial. If interest, I can cover this…
RT @sgdambrauskas: Genious @VinayPrasad82 suggestion about non inf trials: 'When you read a non-inferiority study, ask yourself: is the new…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @Vilavaite: @barttels2 It would be great, but even more important would be that published studies have statistical rigor It is incredibl…
RT @sandeepdasmd: Good article on non-inferiority trials @ambarish4786 @rohan_khera @JainySavlaMD https://t.co/G2FCF11HlV
Caution needed interpreting non-inferiority #clinicaltrials https://t.co/bkC0Un87MW
RT @sgdambrauskas: Genious @VinayPrasad82 suggestion about non inf trials: 'When you read a non-inferiority study, ask yourself: is the new…
RT @ProfDFrancis: Shrewd article from Vinay Prasad on what to consider when reading a non-inferiority trial. If interest, I can cover this…
RT @sgdambrauskas: Genious @VinayPrasad82 suggestion about non inf trials: 'When you read a non-inferiority study, ask yourself: is the new…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
RT @sgdambrauskas: Genious @VinayPrasad82 suggestion about non inf trials: 'When you read a non-inferiority study, ask yourself: is the new…
Good article on non-inferiority trials @ambarish4786 @rohan_khera @JainySavlaMD https://t.co/G2FCF11HlV
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy? from @VinayPrasad82 https://t.co/FhFI7vKUoL
Excellent discussion of the perils of non-inferiority trials!! https://t.co/vG5BXqhI9E
Great overview of the problems associated with non-inferiority trial design and interpretation by Dr. Vinay Prasad in JGIM. https://t.co/E7HWl7xPml https://t.co/3jF9Lb1ObN
RT @SVRaoMD: His point, made well, is that noninferiority has become a crutch with margins that are gamed. It’s a valuable technique but on…
RT @PabloACoello: Caution with non-inferiority trials. Empirical research and editorial https://t.co/dmAjBbicp7 @CochraneIberoam @GRADE_WG…
RT @RogueRad: Clear explanation of non inferior trials by @VinayPrasad82., which seem like RCT's version of participation trophies https://…
@barttels2 It would be great, but even more important would be that published studies have statistical rigor It is incredible what @VinayPrasad82 says in the article shared by @RogueRad yesterday Statistics used to bring new but not better treatments into
"When you read a non-inferiority #trial ask yourself: Is the new #therapy cheaper, more convenient, less invasive, or less toxic than the older one? If no, read no further Finally ask yourself if the intervention was actually inferior" @VinayPrasad82 https
RT @ProfDFrancis: Shrewd article from Vinay Prasad on what to consider when reading a non-inferiority trial. If interest, I can cover this…
RT @david_colquhoun: "97% of industry-sponsored non-inferiority trials" find the test treatment is not inferior. They are useless https://…
Shrewd article from Vinay Prasad on what to consider when reading a non-inferiority trial. If interest, I can cover this in a tweetorial in future. https://t.co/BTYKwYEbs9
Excellent explanation on why we should take non inferiority trials results extremely carefully. Bottom line is: if it’s not clearly cheaper, safer, less invasive or easier, stop reading. If the margin is too large, forget it. https://t.co/pIH3hEVjlE
RT @RogueRad: Clear explanation of non inferior trials by @VinayPrasad82., which seem like RCT's version of participation trophies https://…
RT @billmeikrantz: “Is the new therapy cheaper, more convenient, less invasive, or less toxic than the older one? If the answer is no, read…
RT @sgdambrauskas: Genious @VinayPrasad82 suggestion about non inf trials: 'When you read a non-inferiority study, ask yourself: is the new…
RT @SVRaoMD: His point, made well, is that noninferiority has become a crutch with margins that are gamed. It’s a valuable technique but on…